Vitiligo therapy with oral and topical phenylalanine with UVA exposure

Int J Dermatol. 1989 Oct;28(8):545-7. doi: 10.1111/j.1365-4362.1989.tb04613.x.

Abstract

The administration of phenylalanine (Phe) combined with UVA exposure was found to be effective in treating vitiligo. Twenty-one patients with vitiligo were divided in two groups: eleven patients were treated with oral L-Phe in a dose of 100 mg/kg body weight and with UVA exposure and ten patients were treated with oral L-Phe in a dose of 100 mg/kg body weight and with UVA exposure. In addition, in the second group, a cream containing 10% L-Phe was applied to the vitiliginous areas. The best results occurred in the second group. No side effects were found in either group.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Administration, Oral
  • Administration, Topical
  • Adolescent
  • Adult
  • Child
  • Combined Modality Therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • PUVA Therapy*
  • Phenylalanine / administration & dosage*
  • Time Factors
  • Vitiligo / therapy*

Substances

  • Phenylalanine